
T-Heart Appoints Sarah Sorrel as Independent Board Member



T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.

Sarah Sorrel has more than 30 years' experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University.

Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasibility Study, bringing a valuable experience and expertise to its execution. Soad El Ghazouani, CEO of T-Heart said: *"We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah's experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic."*

Ms. Sorrel added: *"I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next key step in the transcatheter heart valve field. I look forward to contributing to T-Heart's important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. "*

Ms. Sorrel is the third female out of five representatives to join the board of T-Heart.

Source: [T-Heart](#)

Published on : Tue, 29 Nov 2022